High dose angiotensin-converting enzyme inhibition prevents fluid volume expansion in heart transplant recipients

Braith, Randy W.; Mills, Roger M.; Wilcox, Christopher S.; Mitchell, M. J.; Hill, James A.; Wood, Charles E.

doi:10.1016/s0735-1097(00)00753-1

Cited by 13 publications

(14 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Besides these potentially renal‐sparing advantages of ACE inhibitors and ARBs, other documented renal benefits in heart transplant recipients include enhanced sodium excretion, as well as uricosuria that was associated with a lowering of plasma uric acid levels (63–65). These are desirable therapeutic effects given that volume overload and gout are both well‐recognized complications in this patient population.…”

Section: Treatment Of Kidney Disease In Heart and Lung Transplant Recmentioning

confidence: 99%

Kidney Disease After Heart and Lung Transplantation

Bloom

Doyle

2006

American Journal of Transplantation

105

View full text Add to dashboard Cite

Kidney disease is a commonly recognized complication of heart and lung transplantation and is associated with increased morbidity and mortality. While the spectrum of kidney disease in this population is wide-ranging, studies indicate that between 3% and 10% of these patients will ultimately develop endstage renal disease (ESRD). This review examines the risk factors for both acute and chronic kidney injury, with a particular emphasis on the role of calcineurin inhibitor-mediated nephrotoxicity in both these settings. Against the background of current National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines, we have further considered and recommended appropriate strategies for longterm management of kidney disease-related manifestations in heart and lung transplant recipients. Specific aspects addressed include retarding progressive renal injury and minimizing nephrotoxicity, as well as treatment of hypertension, hyperlipidemia and anemia. Finally, for patients in this population with advanced kidney disease, renal replacement therapy options are discussed. Based on the impact of chronic kidney disease on outcomes in both heart and lung recipients, we advocate early referral to a nephrologist for patients displaying evidence of significant renal dysfunction.

show abstract

Section: Treatment Of Kidney Disease In Heart and Lung Transplant Recmentioning

confidence: 99%

Kidney Disease After Heart and Lung Transplantation

Bloom

Doyle

2006

American Journal of Transplantation

105

View full text Add to dashboard Cite

show abstract

“…Many humoral and neural mechanisms in HTx recipients may keep contributing to changes on the vessel wall. First, abnormal responsiveness of the renin-angiotensin-aldosterone system (RAAS) to fluid retention exists in HTx recipients 14 . This will ultimately lead to reabsorb more Na + and water from the urine.…”

Section: Discussionmentioning

confidence: 99%

The detection of coronary stiffness in cardiac allografts using MR imaging

Lin

Lloyd‐Jones

Taimen

et al. 2014

European Journal of Radiology

View full text Add to dashboard Cite

Objective To test the hypothesis that biomechanical changes are quantitatively related to morphological features of coronary arteries in heart transplant (HTx) recipients. Materials and methods With IRB approval, three-dimensional (3D) magnetic resonance (MR) angiography and two-dimensional (2D) black-blood stead-state free precession (SSFP) MR imaging were performed to image coronary arteries of 36 HTx patients. Contours of coronary wall were manually drawn. For each coronary segment, coronary wall thickness, wall area, lumen area (in systole and diastole) were acquired. Coronary distensibility index (CDI) and the percent of the coronary wall occupying the vessel area (PWOV) were calculated. Results There are totally 98 coronary segments eligible for quantitative analysis from 27 HTx patients. The CDI is 4.90 ± 2.44 mmHg−1. The mean wall thickness is 1.49 ± 0.24 mm and the PWOV is 74.6% ± 7.5%. CDI has moderate correlations with wall thickness (r = −0.531, P < 0.001) and with PWOV (R = −0.435, P < 0.001). Conclusions Detected with coronary MR imaging, CDI is quantitatively correlated with the morphological features of the coronary artery in HTx patients. Coronary stiffness has the potential to become an alternative imaging biomarker for the quantitative assessment of the status of cardiac allografts.

show abstract

“…R.W. Braith и соавторы в пере-крестном исследовании показали, что у реципиен-тов трансплантированного сердца с артериальной гипертонией объем внутрисосудистой жидкости увеличивается в среднем на 12% [15], а назначение ингибитора ангиотензинпревращающего фермента (иАПФ) каптоприла восстанавливает эуволюмиче-ское состояние. Указанные факты свидетельствуют о важной роли РААС в патогенезе АГ и ее осложне-ний у реципиентов трансплантированного сердца.…”

Section: увеличение объема циркулирующей кровиunclassified

Hypertension in cardiac transplant recipients

Шевченко

Никитина

Тюняева

2017

RJTAO

View full text Add to dashboard Cite

1 ФГБУ «Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России, Москва, Российская Федерация 2 ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский университет), Москва, Российская ФедерацияАртериальная гипертония -один из наиболее распространенных патологических синдромов среди реци-пиентов трансплантированноого сердца, как взрослых, так и детей. Хроническое повышение артериаль-ного давления является важным модифицируемым фактором риска дисфункции сердечного трансплан-тата, васкулопатии, жизнеопасных нарушений ритма, мозгового инсульта, почечной недостаточности и смерти. Данная статья построена на обзоре литературы и посвящена особенностям патогенеза, профи-лактики, немедикаментозной и лекарственной терапии посттрансплантационной артериальной гиперто-нии у реципиентов сердца.Ключевые слова: трансплантация сердца, реципиент сердца, артериальная гипертония, профилактика, лечение.

show abstract

High dose angiotensin-converting enzyme inhibition prevents fluid volume expansion in heart transplant recipients

Cited by 13 publications

References 23 publications

Kidney Disease After Heart and Lung Transplantation

Kidney Disease After Heart and Lung Transplantation

The detection of coronary stiffness in cardiac allografts using MR imaging

Hypertension in cardiac transplant recipients

Contact Info

Product

Resources

About